Cancer Clinical Trials

When the way forward isn’t clear…

Maybe a clinical trial is right for you.

If you or a loved one has cancer and the current treatment option isn’t working, a clinical trial might be right for you. Clinical trials offer the latest therapy to improve on the standard of care and to test how new medical approaches work when other methods have failed. Clinical treatments have resulted in new treatments and prevention options for cancer care.

Participation in a cancer clinical trial also offers more interactive, precise and personalized care for you. Your treatment team is broader, coming from a range of disciplines. This allows more individualized attention to your care. A Phase I clinical trial can also allow you to stay closer to your home setting without having to travel to another destination.

If you are interested in learning more about a clinical trial, complete the form below or call (864) 920-2523. (This number is answered Monday through Friday, 8:30 a.m. to 5 p.m.  Please leave a voice message after business hours and your call will be returned within two business days.)

View below all of our active clinical trials.

Request Information on Clinical Trials

Someone will contact you within two business days.

How May We Help You?

Contact us: (864) 920-2523

Monday through Friday, 8:30 a.m. to 5 p.m.
or leave a message after business hours if you need active treatment for cancer. These trials do not pay you for participation.

Learn more about Clinical Trials

Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.

Clinical Trials Available

Current Clinical Trials

Disease SiteStudyLocation
Disease Site: Lung: Non-Small Cell

CTSU E4512   View on ClinicalTrials.gov
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

OP Cancer Institute Research
864-241-6251
Disease Site: CML

CTSU EA9171   View on ClinicalTrials.gov
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

OP Cancer Institute Research
864-241-6251
Disease Site: AML

USO 18168/AbbVie M19-072   View on ClinicalTrials.gov
A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy

OP Cancer Institute Research
864-241-6251
Disease Site: Graft vs Host

INCYTE INCB 18424-MA-GD-301   View on ClinicalTrials.gov
An Open-label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

OP Cancer Institute Research
864-241-6251
Disease Site: Supportive Care

CTSU EAQ171CD   View on ClinicalTrials.gov
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0

OP Cancer Institute Research
864-241-6251
Disease Site: Lymphoma

USO 16065/TG Therapeutics UTX-TGR-205   View on ClinicalTrials.gov
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

OP Cancer Institute Research
864-241-6251
Disease Site: Supportive Care

SWOG S1501   View on ClinicalTrials.gov
PROSPECTIVE EVALUATION OF CARVEDILOL IN PREVENTION OF CARDIAC TOXICITY IN PATIENTS WITH METASTATIC HER-2+ BREAST CANCER, PHASE III

OP Cancer Institute Research
864-241-6251
Disease Site: Lung: Non-Small Cell

Roche GO29537   View on ClinicalTrials.gov
A PHASE III, MULTICENTER, RANDOMIZED,OPEN-LABEL STUDY EVALUATING THE EFFICACYAND SAFETY OF ATEZOLIZUMAB (MPDL3280A,ANTI!PD-L1 ANTIBODY) IN COMBINATION WITHCARBOPLATIN∀ NAB-PACLITAXEL FORCHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IVNON-SQUAMOUS NON!SMALL CELL LUNG CANCER

OP Cancer Institute Research
864-241-6251
Disease Site: Solid Tumors

SWOG S1609   View on ClinicalTrials.gov
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS

OP Cancer Institute Research
864-241-6251
Disease Site: Prostate

Suzhou Kintor Pharmaceutical, Inc. GT0918-US-1002   View on ClinicalTrials.gov
An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide

OP Cancer Institute Research
864-241-6251